New start-up founded Biozentrum, University of Basel: SEAL Therapeutics AG develops an innovative gene therapy to treat life-threatening muscular dystrophy #LAMA2_MD. The goal of the founders is to bring their new treatment approach from the lab to patients. Rüegg Lab University of Basel biozentrum.unibas.ch/news/detail/th…

Linker proteins not only correct muscular dystrophy but also nerve pathology in mouse models for LAMA2 MD/MDC1A. See our latest preprint: biorxiv.org/content/10.110… Thanks to Emanuela and Stefano Stefano Previtali from the Previtali lab for the great collaboration.

Last day to submit your abstract! Join us in Ascona: musclewasting.ch from 11-16 September, 2022 #myotwitter #muscleresearch #musclewasting

We are pleased to announce that we have received a research grant in the amount of $293,810.00 from the Muscular Dystrophy Association for our study, “Linker-based gene therapy of LAMA2-related muscular dystrophy using AAVMYO”. Thank you Muscular Dystrophy Association

President’s Award for the best fundamental work from World Muscle Society at the #WMS2022 in Halifax to Judith Reinhard for her work on the development of a potential treatment for LAMA2 MD. #LAMA2 #MDC1A SEAL Therapeutics AG. Congratulations!👋👋👋

Wer an LAMA2-Muskel­dystrophie leidet, dem fehlt das Gerüst-#Protein Laminin α2. Via #Gentherapie mit künstlich generierten Linker-#Proteinen will SEAL Therapeutics (SEAL Therapeutics AG), ein #Spinoff der Universität Basel, dessen Funktion ersetzen… @SigridMaerz fragt nach: laborjournal.de/editorials/278…

Zum #TagDerSeltenenKrankheiten rücken wir die LAMA2-Muskeldystrophie in den Fokus. Bislang gibt es keine Therapie für die genetisch bedingte Erkrankung. SEAL Therapeutics AG, ein Start-up der Universität Basel, verfolgt nun einen vielversprechenden Ansatz. 🧵 1/6 unibas.ch/de/Aktuell/New…

On #RareDiseaseDay, we are putting the spotlight on LAMA2 muscular dystrophy. As yet, there are no effective therapies for this genetic disease. SEAL Therapeutics AG, a University of Basel start-up, is now pursuing a promising approach. 🧵 1/7 unibas.ch/en/News-Events…

Check out our latest publication where we use single-nuclei RNA-seq to study gene expression at the neuromuscular junction: nature.com/articles/s4146… The paper also characterizes three novel NMJ proteins including the transcription factor ETV4 and the MuSK-binding protein PDZRN4.

Rüegg Lab identified over 450 genes that maintain a stable connection between nerves and muscles. The study provides insights for the treatment of neuromuscular diseases such as #ALS, muscular dystrophies & #sarcopenia. University of Basel Swiss National Science Foundation Nature Communications biozentrum.unibas.ch/news/detail/nu…

If you're using AAVs to develop a gene therapy or to study gene function in skeletal muscle, then this may be of interest to you. In our latest work, we show that AAVs commonly used to deliver transgenes to muscle fibers also target mononuclear cells: cell.com/molecular-ther…

Myc and muscle growth: necessary in muscle stem cells, dispensable in muscle fibers and harmful if overexpressed. Check out our latest work rdcu.be/eggcw in Nature Communications, where we explore the role of Myc in muscle growth and more.